SCHEMBL4131556

SCHEMBL4131556

NC(=O)c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.60
L3MBTL3 Q96JM7 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MBTD1 Q05BQ5 1/20 0.49
TP53BP1 Q12888 1/20 0.49
L3MBTL4 Q8NA19 1/20 0.49
ITGB3 P05106 4/20 0.47
ITGA2B P08514 4/20 0.47
ALOX15 P16050 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CHRNA7 P36544 1/20 0.43
CHRNA10 Q9GZZ6 1/20 0.43
CHRNA9 Q9UGM1 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
FFAR4 Q5NUL3 1/20 0.41
MMP2 P08253 1/20 0.41
MMP13 P45452 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123114 0.88 HRH3 (0.56) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4136511 0.86 KMT2A (0.62) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4123123 0.84 HRH3 (0.59) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4147049 0.84 L3MBTL3 (0.67) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4048623 0.84 HRH3 (0.62) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4136937 0.83 HRH3 (0.50) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4130409 0.83 HRH3 (0.49) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4141350 0.83 KMT2A (0.58) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4130681 0.83 L3MBTL3 (0.66) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4139958 0.83 L3MBTL3 (0.66) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885L3MBTL3 2655/4885L3MBTL1 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.